2025/1/31 TaiRx’s orally administered anticancer drug, CVM-1118 (Foslinanib), was officially granted Orphan Drug Designation (ODD) by the U.S. […]
2024/7/17 TaiRx, Inc. hereby declares that Zelnite® is the only selenium injection product with a drug license approved by the Ministry of Health and Welfare (MOHW) in [...]
2024/5/9 In 2018, TaiRx received approval from the Food and Drug Administration (TFDA) of the Ministry of Health and Welfare for a new drug license, Zelnite® for [...]
2022/12/23 In December 2022, TaiRx’s proprietary sodium selenite pentahydrate, with the registered trademark SelenOne®, received the Symbol of National Quality (SNQ). The certification [...]
2020/12/9 Andrew Lin received his master’s degree of Business Administration (MBA) from the University of Chicago. He is one of the very few [...]
2020/12/1 Having been awarded the 12th National Innovation Award in 2015 and the Excelsior Award in 2019, TaiRx’s anti-cancer drug CVM-1118 won the [...]
2020/11/27 To enrich working capital, TaiRx has successfully raised 504 million NTD on October 28, 2020, and issued common shares on November 27, [...]
2019/8/30 World-renowned professional information services company, Clarivate Analytics, released a special report, “Pharmaceutical Innovation in the APAC Region – A Quantitative Company Ranking [...]
2019/1/2 TaiRx, Inc. (6580) announces good news at the start of 2019 that it receives “Technology and Product or Technology Development is Successful [...]
2018/10/23 TaiRx, Inc and BioHealth Innovation, Inc. (BHI) announced today the formation of TaiRx US, a new joint venture. The mission of the [...]
